18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Nuclear Medicine

• Publication date

  2011-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2967/jnumed.110.082586PMID 21321279PMCID PMC4019941
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Involved Field Radiotherapy Versus No Further Treatment in Patients with Clinical Stages IA and IIA Hodgkin Lymphoma and a ‘Negative’ PET Scan After 3 Cycles ABVD. Results of the UK NCRI RAPID Trial

  2012cited by this paper
• Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP.

  2012cited by this paper
• Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma.

  2010cited by this paper
• Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study.

  2010cited by this paper
• High incidence of false-positive PET scans in patients with aggressive non-Hodgkin's lymphoma treated with rituximab-containing regimens.

  2009cited by this paper
• PET Scan Results of NCCTG N0489: Epratuzumab and Rituximab in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone Chemotherapy (ER-CHOP) in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma.

  2009cited by this paper
• Early 18fluorodeoxyglucose PET Scan as a Prognostic Tool in Diffuse Large B-Cell Lymphoma Patients Treated with An Anthracycline-Based Chemotherapy Plus Rituximab.

  2009cited by this paper
• Report on the First International Workshop on interim-PET scan in lymphoma

  2009cited by this paper
• Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review.

  2009cited by this paper
• Phase II study of risk-adapted therapy of newly diagnosed, aggressive non-Hodgkin lymphoma based on midtreatment FDG-PET scanning.

  2009cited by this paper
• Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?

  2009cited by this paper
• Interim 18-FDG-Positron Emission Tomography/Computed Tomography (PET) Failed to Predict Different Outcome in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab-CHOP.

  2009influential reference
• Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no further treatment) in Patients with Clinical Stages 1A and 2A Hodgkin Lymphoma and a ‘negative’ FDG-PET Scan after 3 Cycles ABVD

  2008cited by this paper
• 18F-FDG PET for Posttherapy Assessment of Hodgkin's Disease and Aggressive Non-Hodgkin's Lymphoma: A Systematic Review

  2007influential reference
• Therapeutic evaluation and prognostic value of interim hybrid PET/CT with 18F-FDG after three to four cycles of chemotherapy in non-Hodgkin's lymphoma

  2007cited by this paper
• Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma.

  2007cited by this paper
• Early 18F-FDG PET for Prediction of Prognosis in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment Versus Visual Analysis

  2007cited by this paper
• Revised response criteria for malignant lymphoma.

  2007cited by this paper
• 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review.

  2006cited by this paper
• FDG‐PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease

  2006cited by this paper
• A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B‐cell lymphoma

  2006cited by this paper
• Prognostic value of early 18 fluorodeoxyglucose positron emission tomography and gallium-67 scintigraphy in aggressive lymphoma: a prospective comparative study

  2006cited by this paper
• FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

  2005cited by this paper
• [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome.

  2005cited by this paper
• Early restaging positron emission tomography with ( 18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's lymphoma.

  2002cited by this paper
• CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

  2002cited by this paper
• Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.

  2000cited by this paper
• 18-FDG-PET as a Prognostic Indicator in the Treatment of Aggressive Non-Hodgkin's Lymphoma-Comparison with CT

  2000cited by this paper
• A predictive model for aggressive non-Hodgkin's lymphoma.

  1993cited by this paper

• 18F-FDG PET/CT for predicting prognosis of B-cell non-Hodgkin lymphoma patients treated with chimeric antigen receptor T cells: the value of pre-infusion and M1 image

  2025cites this paper
• Early Positron Emission Tomography Response-Adapted Treatment in Low-Risk Diffuse Large B-Cell lymphoma: an open label, multicenter, randomised, non-inferiority phase 3 trial.

  2025cites this paper
• Risk Stratification for Diffuse Large B‐Cell Lymphoma by Integrating Interim 18F‐FDG PET‐CT Analysis and the NCCN‐IPI: A Multicenter Retrospective Study

  2025cites this paper
• Diffuse large B-cell lymphoma involving osseous sites: utility of response assessment by PET/CT and good longterm outcomes

  2023cites this paper
• Application of interim PET-CT in first-line treatment decision-making for lymphoma

  2023cites this paper
• Hodgkin lenfoma hastalarında maksimum tümör çapı ve 18F-FDG PET/BT görüntüleme durumunun genel sağkalıma etkisi

  2023cites this paper
• F-18 FDG PET/CT in staging and response assessment of primary cutaneous diffuse large B-cell lymphoma (leg type)

  2023cites this paper
• Role of interim PET/CT as predictor of outcome in newly diagnosed diffuse large b-cell lymphoma in the chemo-immunotherapy era.

  2023cites this paper
• PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design

  2022cites this paper
• The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review

  2022cites this paper
• Interim FDG18-PET SUVmax Variation Adds Prognostic Value to Deauville 5-Point Scale in the Identification of Patients with Ultra-High-Risk Diffuse Large B Cell Lymphoma.

  2022cites this paper
• 18F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study

  2021cites this paper
• End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA.

  2021cites this paper
• Correlation of 18-fluorodeoxyglucose PET/computed tomography parameters and clinical features to predict outcome for diffuse large B-cell lymphoma

  2021cites this paper
• Quantitative Whole-Body Diffusion-weighted MRI after One Treatment Cycle for Aggressive Non-Hodgkin Lymphoma Is an Independent Prognostic Factor of Outcome.

  2021cites this paper
• PET CT in Non-Hodgkin Lymphoma

  2021cites this paper
• Imaging Assessment of Tumor Response in the Era of Immunotherapy

  2021cites this paper
• Positron emission tomography/computed tomography in the management of Hodgkin and B‐cell non‐Hodgkin lymphoma: An update

  2021cites this paper
• [18F]FDG PET-CT in patients with DLBCL treated with CAR-T cell therapy: a practical approach of reporting pre- and post-treatment studies

  2021cites this paper
• FDG-PET/CT in Assessment of Treatment Response in Pediatric Lymphoma

  2021cites this paper
• Prognostic value of interim FDG PET-CT in patients older than 60 years with diffuse large B-cell lymphoma treated by PMitCEBO plus rituximab. Comparison between Deauville 5-point scale and International Harmonization Project criteria.

  2021cites this paper
• Therapy Response Imaging in Lymphoma and Hematologic Malignancies

  2020cites this paper
• Interim response in diffuse large B cell lymphoma on CT: what is the optimal size reduction (ΔSPD) for predicting outcome?

  2020cites this paper
• Interim PET/CT result is the sole prognostic factor of survival in patients with advanced-stage diffuse large B-cell lymphoma: a subset analysis of a prospective trial

  2020cites this paper
• Utilité pronostique de la [18F] fluorodeoxyglucose tomographie par émission de positon/tomodensitométrie pré transplantation chez les patients atteints d’un lymphome B diffus à grandes cellules traités par rituximab, dexamethasone, cytarabine à haute dose, carboplatine en chimiothérapie de sauvetage

  2020cites this paper
• Posttreatment FDG-Avid Splenic Lesions in DLBCL and HD: Clinical and Radiographic Characteristics for Risk Assessment.

  2020cites this paper
• Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction.

  2019cites this paper
• Interim PET/CT Result Is The Sole Prognostic Factor Of Survival In Patients With Advanced-Stage Diffuse Large B-cell Lymphoma：A Prospective Trial

  2019cites this paper
• Predictive value of interim FDG-PET/CT findings in patients with diffuse large B-cell lymphoma treated with R-CHOP

  2019cites this paper
• Hybrid Imaging and Radionuclide Therapy in Hemato-oncology

  2019cites this paper
• Interim PET/CT based on visual and semiquantitative analysis predicts survival in patients with diffuse large B‐cell lymphoma

  2019cites this paper
• JSH practical guidelines for hematological malignancies, 2018: II. Lymphoma-5—diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS)

  2019cites this paper
• End-of-Treatment PET/Computed Tomography Response in Diffuse Large B-Cell Lymphoma.

  2019cites this paper
• Prognostic significance of locally invaded sites and tissue types in patients with nasal extranodal natural-killer/T-cell lymphoma: a single-center retrospective analysis

  2019cites this paper
• fluorodeoxyglucose positron emission tomography ‐ computed tomography for the prediction of complete response and survival in patients with diffuse large B ‐ cell lymphoma

  2018cites this paper
• Predictive value of interim positron emission tomography in diffuse large B-cell lymphoma: a systematic review and meta-analysis

  2018cites this paper
• Metabolic Tumor Volume Metrics in Lymphoma.

  2018cites this paper
• ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.

  2018cites this paper
• Post-therapy lesions in patients with non-Hodgkin’s lymphoma characterized by 18F-FDG PET/CT-guided biopsy using automated robotic biopsy arm

  2018cites this paper
• PET/CT in Lymphoma: Current Overview and Future Directions.

  2018cites this paper
• Prognostic value of interim fluorodeoxyglucose and fluorothymidine PET/CT in diffuse large B-cell lymphoma.

  2018cites this paper
• Comparison Between Different PET and CT-Based Imaging Interpretation Criteria at Interim Imaging in Patients With Diffuse Large B-Cell Lymphoma

  2018cites this paper
• Monitoring clinical outcomes in aggressive B-cell lymphoma: From imaging studies to circulating tumor DNA.

  2018cites this paper
• End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry

  2017cites this paper
• Synthetic lethal treatment strategies for tumor cell senescence

  2017cites this paper
• Clinical characteristics of aggressive Non-Hodgkin lymphoma with emphasis on the role of positron emission tomography/computed tomography in assessment of treatment response: a retrospective study

  2017cites this paper
• Contrast-enhanced ultrasound in the therapeutic assessment of diffuse large B-cell lymphoma: A case report

  2017cites this paper
• 18F-FDG PET/CT in the clinical management of patients with lymphoma

  2017cites this paper
• Combinación de tomografías simple y por emisión de positrones en la evaluación de la respuesta temprana al tratamiento del linfoma no Hodgkin

  2017cites this paper
• Interim PET-driven strategy in de novo diffuse large B-cell lymphoma: do we trust the driver?

  2017influential citation
• FDG-PET for Early Response Assessment in Lymphomas: Part 2-Diffuse Large B-Cell Lymphoma, Use of Quantitative PET Evaluation.

  2017cites this paper
• Assessment of chemotherapy response in non-Hodgkin lymphoma involving the neck utilizing diffusion kurtosis imaging: a preliminary study.

  2017cites this paper
• Evaluating early interim fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography with the SUVmax-liver-based interpretation for predicting the outcome in diffuse large B-cell lymphoma

  2017cites this paper
• Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14

  2017cites this paper
• Response Assessment Criteria and Their Applications in Lymphoma: Part 2

  2017cites this paper
• Advancing Precision Nuclear Medicine and Molecular Imaging for Lymphoma.

  2017cites this paper
• The Association Between Liver and Tumor [18F]FDG Uptake in Patients with Diffuse Large B Cell Lymphoma During Chemotherapy

  2017cites this paper
• Predictive value of interim PET/CT visual interpretation in the prognosis of patients with aggressive non-Hodgkin’s lymphoma

  2017cites this paper
• 18F-FDG PET/CT in the clinical management of patients with lymphoma.

  2017cites this paper
• An evidence-based review on the value of interim FDG-PET in assessing response to therapy in lymphoma.

  2017cites this paper
• Elevated tumor-to-liver uptake ratio (TLR) from 18F–FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection

  2017cites this paper
• Prognostic value of whole-body SUVmax of nodal and extra-nodal lesions detected by 18F-FDG PET/CT in extra-nodal NK/T-cell lymphoma

  2016cites this paper
• Clinical approach to diffuse large B cell lymphoma.

  2016cites this paper
• Guidelines for the management of diffuse large B‐cell lymphoma

  2016cites this paper
• ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.

  2016cites this paper
• Circulating Tumor DNA to Monitor Therapy for Aggressive B-Cell Lymphomas

  2016cites this paper
• Different predictive values of interim 18F-FDG PET/CT in germinal center like and non-germinal center like diffuse large B-cell lymphoma

  2016cites this paper
• FDG PET/CT response in diffuse large B-cell lymphoma

  2016cites this paper
• FDG PET/CT Findings in Primary Diffuse Large B-cell Lymphoma, Leg Type.

  2016cites this paper
• Imaging of primary pediatric lymphoma of bone

  2016cites this paper
• Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL

  2016cites this paper
• Interim PET Scans in Diffuse Large B-Cell Lymphoma: Is It Ready for Prime Time?

  2016cites this paper
• Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring.

  2016cites this paper
• Interim18 F-FLUORO-2-deoxy-d-glucose positron emission tomography scan/computed tomography scan in diffuse large B cell lymphoma-as a prognostic tool.

  2016cites this paper
• Role of Positron Emission Tomography in Diffuse Large B-cell Lymphoma.

  2016cites this paper
• Biological correlation between glucose transporters, Ki-67 and 2-deoxy-2-[18F]-fluoro-D-glucose uptake in diffuse large B-cell lymphoma and natural killer/T-cell lymphoma.

  2016cites this paper
• Clinical presentation and staging of Hodgkin lymphoma.

  2016cites this paper
• Prognostic value of interim FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: Systematic review and meta-analysis.

  2016cites this paper
• PET-CT in Staging, Response Evaluation, and Surveillance of Lymphoma

  2016cites this paper
• Does Radiation Have a Role in Advanced Stage Hodgkin’s or Non-Hodgkin Lymphoma?

  2016cites this paper
• Personalized Management Approaches in Lymphoma: Utility of Fluorodeoxyglucose-PET Imaging.

  2016cites this paper
• Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC)

  2016cites this paper
• PET Scans for Staging and Restaging in Diffuse Large B-Cell and Follicular Lymphomas

  2016cites this paper
• Imaging in Nuclear Medicine-ReadingSample

  2016cites this paper
• Recommendations to stage and assess the response to therapy of lymphomas with [18F]FDG-PET-CT

  2016cites this paper
• PET-Derived Metabolic Volume Metrics in the Hodgkin Lymphoma

  2016cites this paper
• Prospective Study of 3′-Deoxy-3′-18F-Fluorothymidine PET for Early Interim Response Assessment in Advanced-Stage B-Cell Lymphoma

  2016cites this paper
• To PET or Not to PET: Interim Imaging in DLBCL

  2016cites this paper
• Utility of interim and end‐of‐treatment PET/CT in peripheral T‐cell lymphomas: A review of 124 patients

  2015cites this paper
• Assessment of the prognostic capacity of pretreatment, interim, and post-therapy 18F-FDG PET/CT in extranodal natural killer/T-cell lymphoma, nasal type

  2015cites this paper
• Variability of Hepatic 18F-FDG Uptake at Interim PET in Patients With Hodgkin Lymphoma

  2015cites this paper
• Residual Anatomical Disease in Diffuse Large B-Cell Lymphoma Patients With FDG-PET–Based Complete Response After First-Line R-CHOP Therapy: Does It Have Any Prognostic Value?

  2015cites this paper
• Response‐adapted therapy for aggressive non‐Hodgkin's lymphomas based on early [18F] FDG‐PET scanning: ECOG‐ACRIN Cancer Research Group study (E3404)

  2015cites this paper
• Predictive Value of Interim PET/CT in DLBCL Treated with R-CHOP: Meta-Analysis

  2015cites this paper
• Prognostic values of interim and post-therapy 18F-FDG PET/CT scanning in adult patients with Burkitt’s lymphoma

  2015cites this paper
• Predictive Efficacy of Interim Positron Emission Tomography/Computed Tomography (PET/CT) for the Treatment of Aggressive Lymphoma

  2015cites this paper
• Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study.

  2015cites this paper
• PET-derived metabolic volume metrics in lymphoma

  2015cites this paper
• F-18-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study

  2015cites this paper
• Prognostic value of interim (18)F-FDG-PET in diffuse large B cell lymphoma treated with rituximab-based immune-chemotherapy: a systematic review and meta-analysis.

  2015cites this paper